1973). Circulating concentrations of prostaglandin FM apparently increase slightly during late gestation, with a massive elevation occurring during labour (Green et al., 1974) . Peripheral plasma concentrations of prostaglandins E, and F,, do not change significantly with labour (Mitchell et al., 1978d) , suggesting that the lungs have the capacity to cope with the increased production of prostaglandins at Cervical dilatation during labour (cm) Fig. 1 . Concentrations of prostaglandin F (means s.E.M.) in amnioticjluid obtained by amniotomy before the onset of labour (0) and during sponfaneous (0) and oxyfocin-induced (r) labour [After Keirse (1979) .1 Vol. 8 this time. It should be noted that many uterine tissues have a considerable capacity to metabolize prostaglandins, although the activity of the main enzyme concerned, 15-hydroxyprostaglandin dehydrogenase, does not alter with labour in the tissues studied (Keirse, 1978) .
The discoveries of thromboxane A, (Hamberg et al., 1975) and prostacyclin (prostaglandin I,) (Moncada et al., 1976) as physiologically active metabolic products of prostaglandin endoperoxides (see Scheme 1) have necessitated investigation of their possible roles in parturition. Owing to the extreme lability of thromboxane A, and prostacyclin, measurements have been confined to their respective inactive degradation products, thromboxane B, and 6-oxoprostaglandin F , , . Little change occurs in the circulating concentrations of these compounds during pregnancy and labour (Mitchell et al., 1978a; M. D. Mitchell, unpublished work) .
Amniotic fluid may provide a better reflection of uterine prostaglandin production, and, since it contains negligible prostaglandin-synthesizing and -metabolizing activities, it has been the fluid of choice for measurements. The concentrations of prostaglandins E, F and F M and of arachidonic acid (the precursor fatty acid) are higher in amniotic fluid during labour than before labour, and increase rapidly as labour progresses (Keirse, 1979) (Fig. 1) . Both 6-oxoprostaglandin F,, and thromboxane B, exhibit similar trends in their amniotic-fluid concentrations, with higher values in labour than beforehand, but no progressive increase during labour . Taken in conjunction with previous results, these findings suggest a general enhancement of prostanoid (prostaglandinlike) production in labour, with a preferential flow through the synthetic pathways for formation of prostaglandins E, and F,,.
The precise origin of the raised prostaglandin concentrations in amniotic fluid and peripheral plasma during labour remains uncertain. Decidua, foetal membranes and myometrium (Keirse, 1979 ) have all been postulated as possible sources. Interpretation of measurements of tissue concentrations of prostaglandins, however, must be cautious, since the trauma of excision and handling provides a potent stimulus to prostaglandin release (Piper & Vane, 1971) . By using a method of tissue superfusion, which allows prostaglandins produced by manipulative procedures to be removed before sample collection under steady-state conditions, it has been shown that the amnion is a major source (per unit weight) of prostaglandin E. Moreover, amnion also exhibits a significant increase in its rate of production of 6-oxoprostaglandin F,, when obtained after labour (Mitchell et al., 1 9 7 8~) ( Table 1) . These findings are consistent with the hypothesis that the signal for the onset of human labour lies in the foetal membranes and is associated with prostaglandin release (Liggins et al., 1977) .
The mechanisms controlling prostanoid production during pregnancy and parturition are ill-defined. Factors already implicated include uterine stretch, changing patterns of steroid hormones, cell damage and the availability of free fatty acid substrate (Keirse, 1979) . Furthermore, it has been suggested that prostaglandin synthesis may be tonically suppressed during pregnancy in primates (Robinson el al., 1978) , and, indeed, an endogenous inhibitor of prostaglandin synthesis, previously described in plasma from several species (Saeed et al., 1977) , can be found in plasma from women during late pregnancy (M. D. Mitchell, unpublished work) . It has been shown that amniotomy (rupture of foetal membranes) in women at term (1980) .1 raises prostaglandin concentrations in both amniotic fluid and peripheral plasma within 5min (Turnbull ef af., 1980) (Fig. 2) . Since oxytocin concentrations are unaffected by amniotomy , oxytocin mediation of this effect, as described in the sheep, is unlikely. Hence there would appear to be a local mechanism for the acute control of prostaglandin release within the uterus. Before moving to a description of prostaglandins in the human foetus and neonatal infant, the following points should be noted. Studies with animals have suggested that prostaglandins (particularly prostaglandin E) play an important part in maintaining the patency of the ductus arteriosus during foetal life (Coceani et al., 1976) . This area of research has gained such momentum that the use of prostaglandins and prostaglandin synthase inhibitors to manipulate the ductus in human neonatal infants is now well documented. It has also been postulated that prostaglandins are of importance in the pulmonary and renal function of the foetus and neonatal infant. Furthermore, the potent constrictor properties of most prostaglandins on the umbilical cord have led to the suggestion that cord closure is prostaglandin-dependent.
Investigations of circulating prostaglandins in the human foetus are necessarily limited to measurements in umbilical-cord plasma. It has been established that umbilical plasma concentrations of prostaglandins E, F and FM are greater than those in maternal plasma, and that higher concentrations are found in umbilical plasma obtained after spontaneous vaginal delivery when compared with samples taken at elective Caesarean section . Moreover, a significant arterio-venous difference has been demonstrated for prostaglandin E, with higher umbilical venous concentrations after either spontaneous vaginal delivery or elective Caesarean section. This suggests that the placenta is a major source of the prostaglandin E in the foetal circulation. Neither 6-oxoprostaglandin F,, nor thromboxane B, exhibits a significant arterio-venous difference across the umbilical circulation (Mitchell et al., 1978a . Umbilical plasma concentrations of thromboxane B, exceed circulating concentrations in the mother, but the mode of delivery does not influence measured values. It should be noted that vessels in the umbilical cord produce a full range of prostanoids, with 6-oxoprostaglandin F,, as the major quantitative product . Infants born at term have significantly lower circulating concentrations of prostaglandin E by the sixth post-natal day compared with values at birth . Mean concentrations of prostaglandins F and FM are also lower, although the difference is not significant. These findings are consistent with the suggestion that the placenta is a major source of prostaglandin E in the foetal circulation at birth and that severance at birth leads particularly to lowered concentrations of prostaglandin E. Infants born pre-term (before 37 completed weeks of pregnancy), but uncomplicated by major disease, exhibit similar plasma concentrations of prostaglandins E, F and FM on the sixth day of life. Hence delivery before term does not appear to be associated grossly with an altered capacity for prostaglandin synthesis or metabolism during early neonatal life. At 2 months after delivery pre-term the plasma concentration of prostaglandin E is similar to that of the adult; those of prostaglandins F and FM are significantly lower than at birth, but remain approximately 3-fold those of adult values (Fig. 3) .
Infants born with a patent ductus arteriosus have abnormally high circulating concentrations of prostaglandins E, F and FM (Lucas & Mitchell, 1978~) . Furthermore, falling plasma concentrations of prostaglandin F with rising prostaglandin E concentrations have been reported shortly before clinical symptoms of patent ductus arteriosus appear (Friedman & Demers, 1978; Lucas & Mitchell, 1978b) . Although medical treatment with indomethacin (a prostaglandin synthase inhibitor) consistently lowers prostaglandin concentrations in the plasma, it does not always close the ductus. Moreover, It has been suggested that neonatal infants who develop respiratory distress syndrome have raised plasma concentrations of prostaglandins E and F, with the elevation in prostaglandin F concentration greatly exceeding that of prostaglandin E (Friedman & Demers, 1978) . Another study (Mitchell et al., 1978e) , however, has described normal circulating concentrations of prostaglandin E but with raised concentrations of prostaglandin F and a disproportionate increase in concentrations of prostaglandin FM. Both studies do indicate that respiratory distress syndrome is associated with raised concentrations of a prostaglandin with vasoconstrictor properties (prostaglandin F2J.
